Bayer's Cost Cuts Only Matter If the Numbers Follow

Bayer has spent the past week stacking up announcements — a digital wheat-protection tool, two drug approvals and a raised outlook — and investors now face a single question that ties them all together: can the German group convert a leaner organisation and a fuller product shelf into durable earnings, while Roundup litigation keeps draining resources?

The workforce reduction Bayer has disclosed is a step already taken. What it does for the share price depends on the economic results of the restructuring, not on the headcount figure itself. Anyone betting on further improvement has to separate measures already in motion from profits still to be delivered.

Guidance becomes the yardstick

The most useful test of operational progress is currency-adjusted EBITDA before special items. On 3 November Bayer lifted its 2026 target for that metric to EUR 9.8bn–10.3bn, up from the EUR 9.6bn–10.1bn it had previously guided. That range now serves as the benchmark against which the raised expectations will be judged.

Third-quarter 2026 figures offer an early reference point. EBITDA before special items reached EUR 1.615bn, a gain of 6.9%, while group revenue came in at EUR 10.053bn — both higher than a year earlier. The improvement underpins management's confidence, provided Bayer can keep the momentum going.

Last week's upgrade went beyond the EBITDA line: the company also raised its Pharmaceuticals margin target and its free cash flow guidance, and held out the prospect of lower net financial debt at year-end. Higher earnings goals and an improved expected cash inflow give the product story a financial foundation — but only if the targets are met.

Should investors sell immediately? Or is it worth buying Bayer?

Precision as the common thread

Look past the individual releases and a single idea emerges: narrower, more targeted applications. PrediView, announced on 5 November, is designed to combine field-specific forecasts with a matched fungicide strategy from the 2027 season — digital information feeding directly into the choice of crop-protection approach. In the pharmaceutical pipeline, the same logic applies to sharply defined patient groups.

On 4 November Bayer reported Chinese approval of Sevabertinib as a first-line treatment for adults with advanced HER2-mutant non-small cell lung cancer, with the genetic restriction built into the approved indication. The FDA's green light for Asundexian, granted on Tuesday under the brand name Sunharbo to reduce the risk of a further stroke, fits the same pattern; Bayer describes it as the world's first approved factor XIa inhibitor.

The stages of development differ, and that matters. PrediView is announced for a future season, while the two medicines already carry approvals. Each application must prove itself at the next economic step.

The legal overhang remains the biggest caveat

CEO Bill Anderson said on Tuesday that a court ruling in Missouri is expected before Christmas. Bayer's proposed Roundup settlement framework covers up to USD 7.25bn, and final judicial approval was still outstanding.

That open status defines the risk case. If approval fails to arrive, or the expected decision slips, the hoped-for legal relief shifts accordingly, and operational gains would have to stand against continued uncertainty from the litigation. Missing the raised earnings guidance would weaken the positive reading of the restructuring in much the same way — precisely because Bayer has lifted the bar, delivery carries extra weight. The bear case is a combination of disappointing earnings and no sign-off on the settlement.

A December catalyst could change the calculus

So long as Bayer meets its higher earnings ambition, the operating trend argues for the turnaround now under way. Should that trend reverse, the job cuts lose their force as an argument for stronger profitability. For investors, the weighing therefore rests on results and legal relief at the same time.

The next concrete catalyst is the court decision Anderson expects before Christmas. Approval could advance the proposed framework; any other outcome would demand a fresh assessment of the legal picture. Until then, the bull case holds only on condition that Bayer confirms its operational improvement — and that the pending ruling is priced in as a risk rather than a certainty.

Ad

Bayer Stock: New Analysis - 12 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...